Global Information
회사소개 | 문의 | 비교리스트

케냐 및 나이지리아의 제네릭 의약품 시장 예측(2022년)

Generic Pharmaceutical Market in Kenya and Nigeria, Forecast to 2022

리서치사 Frost & Sullivan
발행일 2019년 04월 상품 코드 824921
페이지 정보 영문 62 Pages
가격
US $ 3,000 ₩ 3,745,000 Web Access (Regional License) help
리서치사의 웹사이트에 로그인할 수 있는 패스워드가 발급되며, PDF를 다운로드 받는 형태로 제공됩니다. 동일 국가 내에 있는 사업장의 모든 분들이 이용할 수 있는 라이선스이며, 이용 인원수 제한은 없습니다. 텍스트 등의 PDF 내용 편집은 불가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


케냐 및 나이지리아의 제네릭 의약품 시장 예측(2022년) Generic Pharmaceutical Market in Kenya and Nigeria, Forecast to 2022
발행일 : 2019년 04월 페이지 정보 : 영문 62 Pages

케냐 및 나이지리아의 제네릭 의약품(Generic Pharmaceutical) 시장에 대해 조사했으며, 시장 개요와 시장 예측, 의약품 공급망의 분석과 논의, 각국의 매출 예측, 주요 동향, 주요 시장 참여 기업, 제휴 전략, 경쟁 환경 및 성장 기회 분석, 전략적 제안과 향후 전망 등에 대해 정리하여 전해드립니다.

제1장 개요

제2장 촉진요인·억제요인

  • 촉진요인
  • 촉진요인 설명
  • 억제요인
  • 억제요인 설명

제3장 케냐 분석

  • 헬스케어 개요
  • 의약품 시장 전체의 개요
  • 제네릭 의약품 시장의 개요
  • 제네릭 vs. 선발의 세분화
  • 매출 예측
  • 매출 예측 논의
  • 주요 제네릭 의약품 제품
  • 의약품 전체 공급망
  • 제네릭 의약품 공급망
  • 공급망 분석
  • 경쟁 환경
  • 경쟁 환경 평가

제4장 나이지리아 분석

  • 헬스케어 개요
  • 의약품 시장 전체의 개요
  • 제네릭 의약품 시장의 개요
  • 제네릭 vs. 선발의 세분화
  • 매출 예측
  • 매출 예측 논의
  • 의약품 전체 공급망
  • 제네릭 의약품 공급망
  • 공급망 분석
  • 경쟁 환경
  • 경쟁 환경 평가

제5장 성장 기회·권장 행동

  • 성장 기회 1 : 민관 제휴
  • 성장 기회 2 : 규제 개혁
  • 성장 기회 3 : API 제조
  • 성장 기회 4 : 백신 제조
  • 성장 기회 5 : 연구개발
  • 의약품 기업의 전략적 필수 요건

제6장 결론

제7장 부록

제8장 FROST & SULLIVAN 소개

KSA 19.05.08

Greater Regulatory Control and a Shift of Focus Away from Costly and Branded Drugs will Increase Generic Drugs' Market Share

The African continent grapples with a huge burden of communicable diseases, particularly HIV/AIDS, tuberculosis, and malaria. With African governments facing major health financing challenges, a significant proportion of these disease areas are financed by global aid organizations that are also helping in poverty eradication in the continent. Parallelly, with each passing year, the incidence of non-communicable diseases has also been on the rise, along with the rising incomes of the African people. With rising incomes, there is greater indulgence in Westernised diets and unhealthy lifestyles that involve high alcohol intake and tobacco smoking.

The pharmaceutical market in Africa has had to keep up with these trends, providing the necessary medicines to combat the various diseases affecting people in African countries. While branded medicines have dominated the pharmaceutical market in the past decades, the current situation seems to favour the generic alternatives instead, as these achieve similar therapeutic outcomes. Taking into consideration the major financing challenges mentioned above, price becomes a key negotiating factor, resulting in governments focusing on acquiring the cheapest drugs in the global market.

Moreover, the supply chains and distribution channels in countries such as Kenya and Nigeria cater to more than 240 million people collectively. These channels are often overwhelmed, particularly with the additional challenges posed by an underdeveloped regulatory environment. This has led to a stronger focus on developing local pharmaceutical capabilities amongst both private and public sectors to cut down on imports that have historically been subject to exchange rate fluctuations. Interest in local manufacturing is growing, and governments are slowly transforming the regulatory environment to create a more conducive operating environment for pharmaceutical investors.

Research Scope:

The study covers the following pharmaceutical therapeutic segments: anti-infective, cancer, cardiovascular, central nervous system, diabetes, and respiratory.

Research Highlights:

  • Market overview and projections for the generic pharmaceutical market (2017-2022)
  • Pharmaceutical supply chain analysis and discussion for Kenya and Nigeria
  • Revenue forecast for the generic pharmaceutical market in each country
  • Key trends, key participants, participant strategies, competitive environment analysis, and growth opportunities
  • Strategic recommendations and future outlook of the generic pharmaceutical market

Key Issues Addressed:

  • What is the generic pharmaceutical market size in Kenya and Nigeria?
  • How is the pharmaceutical supply chain structured in these two countries?
  • Who are the key generic pharmaceutical suppliers in Kenya and Nigeria?
  • Who are the key distributors in the Kenyan and Nigerian generic pharmaceutical markets?
  • What are the key growth opportunities in the Kenyan and Nigerian generic pharmaceutical markets?

Table of Contents

1. EXECUTIVE SUMMARY

  • Key Findings
  • Scope
  • Segmentation
  • Revenue Share by Therapeutic Segment
  • Key Questions this Study will Answer

2. DRIVERS AND RESTRAINTS

  • Key Market Drivers
  • Drivers Explained
  • Drivers Explained (continued)
  • Key Market Restraints
  • Restraints Explained
  • Restraints Explained (continued)

3. KENYA ANALYSIS

  • Healthcare Overview-Kenya
  • Total Pharmaceutical Market Overview-Kenya
  • Generic Pharmaceutical Market Overview-Kenya
  • Generic vs. Branded Segmentation-Kenya
  • Revenue Forecast-Kenya
  • Revenue Forecast Discussion-Kenya
  • Key Generic Pharmaceutical Products-Kenya
  • Total Pharmaceutical Supply Chain-Kenya
  • Generic Pharmaceutical Supply Chain-Kenya
  • Supply Chain Analysis-Kenya
  • Competitive Environment-Kenya
  • Competitive Environment Assessment-Kenya

4. NIGERIA ANALYSIS

  • Healthcare Overview-Nigeria
  • Total Pharmaceutical Market Overview-Nigeria
  • Generic Pharmaceutical Market Overview-Nigeria
  • Generic vs. Branded Segmentation-Nigeria
  • Revenue Forecast-Nigeria
  • Revenue Forecast Discussion-Nigeria
  • Total Pharmaceutical Supply Chain-Nigeria
  • Generic Pharmaceutical Supply Chain-Nigeria
  • Supply Chain Analysis-Nigeria
  • Competitive Environment-Nigeria
  • Competitive Environment Assessment-Nigeria

5. GROWTH OPPORTUNITIES AND COMPANIES TO ACTION

  • Growth Opportunity 1-Public-Private Partnerships
  • Growth Opportunity 2-Regulatory Reform
  • Growth Opportunity 3-API Manufacturing
  • Growth Opportunity 4-Vaccine Manufacturing
  • Growth Opportunity 5-Research and Development
  • Strategic Imperatives for Pharmaceutical Companies

6. THE LAST WORD

  • The Last Word-3 Big Predictions
  • Legal Disclaimer

7. APPENDIX

  • List of Exhibits

8. THE FROST & SULLIVAN STORY

    The Frost & Sullivan Story
  • The Frost & Sullivan Story
  • Value Proposition-Future of Your Company & Career
  • Global Perspective
  • Industry Convergence
  • 360° Research Perspective
  • Implementation Excellence
  • Our Blue Ocean Strategy
Back to Top
전화 문의
F A Q